• Abridge

  Participated · Series B · Oct 2023

  Abridge builds AI scribe technology that automates medical notes and integrates with Epic Systems. The company says its technology is used by over 150 of the largest U.S. health systems. In Q1 Abridge reported $117 million in contracted annual recurring revenue (a metric that includes signed recurring contracts, including customers not yet onboarded). It is expanding into converting medical notes from patient appointments into AI-powered medical codes, a move that positions it against startups like CodaMetrix and features from Epic. Abridge is widely considered a leader in the AI-powered medical scribe market due to early entry and Epic integration. The company was founded by cardiologist Shiv Rao and is seven years old. Abridge provides an enterprise-grade generative AI platform that transforms medical conversations into clinically useful and billable documentation at the point of care. The platform maps AI-generated summaries to source data using Linked Evidence to make outputs auditable and verifiable. It integrates deeply with EHRs, supports 28+ languages and 50+ specialties, and is used across outpatient, emergency department, and inpatient settings. Abridge says it has been deployed in more than 100 health systems, with enterprise implementations at Duke Health, Johns Hopkins, Mayo Clinic, UNC Health and others, representing tens of thousands of clinicians. The company recently introduced a Contextual Reasoning Engine to incorporate retrospective encounters, revenue-cycle rules, and clinician preferences to produce more comprehensive, billable notes and capture orders for EHRs. The Series D funding will support continued AI research and commercial growth to broaden applications and reduce clinician administrative burden. Abridge builds an AI-powered virtual medical scribe and clinical note-taking product that records patient encounters and generates editable visit notes. The company began with a free smartphone transcription app whose usage helped train its proprietary medical LLM on thousands of doctor–patient conversations. Its virtual scribe supports 14 foreign languages and has secured a right to be integrated inside Epic so notes can appear directly in the EHR for clinician verification. Large health systems are buying multi‑thousand-seat licenses, and Abridge has been announcing a new health system customer nearly every week since the start of 2024 (customers named include University of Chicago, Sutter, Yale, Lee Health, Christus and Emory). The company says its product materially reduces physicians’ administrative burden and has been described by customers as “life-changing” and “magical.” Abridge faces competition from incumbents and other AI scribe vendors, and observers note the open question of whether general foundation models could narrow its lead over time. Abridge builds generative AI for clinical documentation, transforming patient–clinician conversations into structured clinical notes in real time with deep EMR integrations. The platform uses Linked Evidence and auditable AI that maps AI-generated summaries to ground truth to help providers trust and verify outputs. Its stack orchestrates language identification, transcription, alignment, diarization, summarization, and verification models to produce and validate notes within seconds, reducing clinician latency from minutes to seconds. Abridge is collaborating with NVIDIA to leverage NVIDIA compute resources, foundation models, and deployment expertise to scale deployments across clinicians in the U.S. and eventually internationally. The company emphasizes research into clinically specialized foundation models, medical speech and language technology, and responsible AI. Abridge was founded in 2018 and is based in Pittsburgh, Pa. Abridge builds AI that captures and summarizes spoken patient–clinician conversations, converting them into structured clinical note drafts in real time. Its audio and ambient AI solutions integrate with EHR systems and allow patients to review notes, medication instructions, treatments, and follow-ups. The company highlights peer-reviewed R&D in medical conversation AI and user experience design. Abridge’s tools support both in-person and telemedicine appointments and aim to free clinicians from clerical work so they can focus on patients. The company says it has spent the last five years developing its technology. SCAN Group began offering Abridge’s service as a supplemental benefit in 2021.

• Monogram Health

  Led · Equity · Jan 2023

  Monogram Health is a value-based specialty provider of in-home evidence-based care and benefit management services for patients with polychronic conditions, including chronic kidney disease and end-stage renal disease. Led by CEO Mike Uchrin, the company deploys an in-home care delivery model and a technology-driven array of evidence-based clinical services such as complex case and disease management, utilization management, and medication therapy management. Monogram has numerous value-based partnerships with health plans and risk-bearing providers to care for patients across 34 states and all insurance products. The company raised $375M in growth funding. It intends to use the proceeds to support widespread deployment of its in-home kidney and polychronic care delivery model and to expand its tech-driven clinical services. Monogram Health provides benefit management and at-home care delivery focused exclusively on chronic kidney disease (CKD) and end-stage renal disease (ESRD). The company partners with health plans to deliver an evidence-based renal care model of clinical managed services, including complex case and disease management, utilization management, and medication therapy management. Leveraging a technology and managed-services platform, Monogram's multidisciplinary clinical team of nurses, nephrologists, dieticians, pharmacists, and social workers coordinates with a patient’s entire care network to slow disease progression and manage individualized needs. Monogram currently operates its renal disease clinical managed services across 20 U.S. states and has built a national network of nephrologists that includes hundreds of specialists. In April the company opened an operations center in Arizona to support its growth in Western states. The company intends to use the Series B proceeds to accelerate business expansion. Monogram Health delivers an at-home renal care model and data-driven care management solutions including complex case management, utilization management, and medication therapy management for patients with chronic kidney and end-stage renal disease. The company partners with health plans, physician practices, dialysis providers and clinically integrated health systems to create personalized care plans and a national network of nephrologists. Monogram uses next-generation artificial intelligence and evidence-based criteria to delay disease progression, optimize transitions to dialysis or transplant, and improve outcomes. It currently operates renal disease care management programs across 20 states and reports a readmission rate for its patients that is half the national average. About 90% of Monogram patients are enrolled in Medicare Advantage plans. Monogram is based in Nashville, Tenn., and is privately held by Frist Cressey Ventures and Norwest Venture Partners. Monogram Health provides kidney disease care management through in-home visits and ongoing clinical engagement, using teams of nurses, social workers, nephrologists, and geriatricians. The company partners with health plans and a national network of nephrologists to deliver cost-effective, integrated care and to improve patient outcomes. Monogram uses next-generation artificial intelligence, clinically integrated care delivery, and personalized care planning to delay disease progression and support transitions to dialysis or pre-emptive transplant. It operates renal disease care management programs for thousands of patients across the U.S., including Humana Medicare Advantage and Commercial members in Louisiana and Mississippi. Monogram emphasizes home-based care to reduce hospitalizations and support vulnerable patients during the COVID-19 pandemic. The company is based in Nashville, Tenn.

• Safely You

  Participated · Series B · Dec 2021

  SafelyYou sells an ambient, AI-powered camera-and-sensor platform that detects when residents might be falling and triggers text and phone alerts to on-call staff. The system does not require wearables and is paired with a remote clinical team that documents falls, reviews videos, conducts root-cause analyses, and issues recommendations. The clinical team has analyzed more than 300,000 on-the-ground events to help reduce future falls. Founder George Netscher says the technology originated in 2015 as part of his doctoral research and the company’s mission is to ensure the highest-quality care for seniors. SafelyYou nearly shut down during the COVID-19 pandemic but survived and now serves nearly 1,000 senior living communities. The company employs roughly 100 people and is San Francisco-based; new capital will support continued expansion. SafelyYou has developed a remote care platform combining real-time AI video technology with a 24/7 remote clinical team to detect and address resident falls. The product is targeted at senior living communities to reduce fall rates and emergency room visits. The company is led by founder and CEO George Netscher and is based in San Francisco, CA. SafelyYou is backed by investors including Eclipse Ventures, Foundation Capital, DCVC, Founders Fund, and Omega Healthcare Investors. The company obtained a $30 million venture loan facility from Horizon Technology Finance, with $10 million initially funded. It intends to use the loan proceeds to expand its business reach. SafelyYou develops an AI-enabled fall management platform that detects falls, analyzes patterns, and pairs technology with professional caregiver intervention to prevent future incidents for seniors and people with Alzheimer’s, dementia, or cognitive impairment. The system combines video review and AI-augmented pattern recognition, reviewing over 1,500 videos of on-the-ground events per month to generate personalized care plans. SafelyYou’s platform is reported to reduce falls by 40% and ER visits from falls by 80%, and a Belmont Village case study found fall-driven ER visits fell to 4% versus an industry average of 17–25%. Beyond detection and prevention, the technology assists caregivers with medication adherence, behavioral monitoring, false-alarm management, memory issues, and occupational therapy support. The company plans to expand availability of its fall-management technology to a wider range of older adults and scale deployments in senior-care facilities. Financially, SafelyYou closed a $30 million Series B in the announced round, bringing its total venture funding to approximately $70 million. SafelyYou offers an AI-enabled fall detection and prevention system specifically designed for memory care and residents with Alzheimer’s disease and related dementias. Its solution uses cameras that only activate when a fall is detected to protect privacy and limit liability. The platform provides post-fall video review to support unwitnessed falls, assist ER decision making, and perform root cause analysis to inform fall prevention. SafelyYou originated in 2015 as the doctoral research of CEO George Netscher at the UC Berkeley Artificial Intelligence Research Lab. The system is already deployed in numerous communities in North America. The company intends to use its new funding to scale its assisted living and skilled nursing business.

• Arine

  Participated · Series A · Oct 2021

  Arine operates an AI-driven medication optimization platform that delivers scalable, personalized medication therapy recommendations to health plans and risk-bearing providers. The platform leverages large, diverse datasets to identify the right individuals, recommend effective interventions, and continuously measure impact. Arine reports outcomes including >10% total cost savings and >40% reduction in hospitalizations, and it experienced >100% growth last year with average contract expansion of 80% with existing clients. The company focuses on improving medication safety, adherence, and effectiveness across populations, including underserved communities. With new funding, Arine plans to expand specialty pharmacy management, accelerate AI innovation to automate high-volume, low-complexity tasks, and integrate additional data to further personalize medication therapy. Arine is a medication intelligence startup that uses its platform to help health plans reduce medication errors, avoid complications, and keep patients out of the hospital. The company serves health plans and risk-bearing providers by improving medication safety and lowering cost of care. Founded in 2017 and based in San Francisco, Arine provides technology to enable better clinical and financial outcomes around medications. Arine plans to use the new funding to advance its platform capabilities to enable value-based care at scale. It intends to expand offerings beyond health plans and providers to other channel partners across the value-based care continuum. The company raised the financing as a mix of equity and debt to support that product and market expansion. Arine is an AI-driven platform that optimizes medication management for health plans and providers. The platform intakes clinical, social, and behavioral data and uses thousands of algorithms to recommend just-in-time clinical interventions for each patient. Those timely interventions are intended to reduce the total cost of care and drive a significant ROI, and the company states it saves one in every six healthcare dollars spent. Arine currently actively manages 5.5M lives. The company plans to use new funding to rapidly scale its team and its technology platform. Its product enables clinicians to provide personalized care by creating a whole picture of each patient based on multi-source data.

No current team members are available.